Sanj K. Patel - Mar 16, 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: Chairman & CEO, Director
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact for Sanj K. Patel
Stock symbol: KNSA
Transactions as of: Mar 16, 2022
Transactions value $: -$19,470
Form type: 4
Date filed: 3/18/2022, 04:38 PM
Previous filing: Sep 7, 2021
Next filing: Mar 23, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+6.57K			6.57K	Mar 16, 2022	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	-$19.5K	-1.92K	-29.26%	$10.13	4.65K	Mar 16, 2022	Direct
holding	KNSA	Class A Common Share						83.3K	Mar 16, 2022	Held by The Anglia 2013 Revocable Trust, u/d/t August 15,2013
holding	KNSA	Class A Common Share						110K	Mar 16, 2022	Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-6.57K	-25%	$0.00	19.7K	Mar 16, 2022	Class A Common Share	6.57K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.